Swiss Life Asset Management’s NovoCure NVCR Stock Holding History

Swiss Life Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-26,752	Closed	-$1.11M	–	635
2023 Q2	$1.11M	Buy	26,752 +1,610	+6%	+$100K	0.02%	529
2023 Q1	$1.51M	Buy	+25,142	New	+$2.01M	0.02%	519
2022 Q4	–	Sell	-3,565	Closed	-$271K	–	619
2022 Q3	$271K	Sell	3,565 -218	-6%	-$17K	﹤0.01%	560
2022 Q2	$264K	Buy	+3,783	New	+$285K	﹤0.01%	573

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Swiss Life Asset Management's NVCR Position: Q3 2023 in Review

Swiss Life Asset Management sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 26,752 shares — an estimated $1.11M sold.

Swiss Life Asset Management first reported a position in NVCR in Q2 2022 and held it in 4 quarters. The position peaked at $1.51M in Q1 2023. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

Swiss Life Asset Management reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
Swiss Life Asset Management sold 26,752 NovoCure shares in Q3 2023, an estimated $1.11M.
Swiss Life Asset Management first reported a position in NovoCure in Q2 2022 and held it in 4 quarters.
Swiss Life Asset Management's NovoCure position peaked at $1.51M in Q1 2023.
226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Swiss Life Asset Management's 13F filing for Q3 2023, filed 9 Dec 2025.